VB-601 / VBL Therap - LARVOL DELTA

VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options (GlobeNewswire) - "VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease."

New P1 trial • Immunology • Inflammatory Bowel Disease

MOSPD2 regulates the activation state of αLβ2 integrin to control monocyte migration (IMMUNOLOGY 2022) - "Employing VB-601, a humanized anti-human MOSDP2 monoclonal antibody, on wild-type THP-1 cells or primary human CD14 monocytes similarly increased cell adhesion to ECM ligands as well as adhesion molecules...Our results reveal a novel regulatory mechanism on monocyte migration in which MOSPD2 governs the balance between monocyte adhesion and release from adhesion molecules and ECM. Targeting MOSPD2 has the potential to treat inflammatory diseases by stemming monocyte infiltration into inflamed tissues."

Inflammation • CD14

"#VBLTherapeutics Announces Successful Completion of Pre-#InvestigationalNewDrug Meeting with #FDA Regarding Proposed Clinical Development of #VB601 $VBLT https://t.co/eiflDldtHg" (@1stOncology)

Clinical • IND